Vitrakvi, a new tissue-agnostic cancer drug — or one that targets tumors caused by TRK fusion — has been approved by the FDA, reports John Bacon for USA Today.
For many patients, this is the only possible treatment for their disease. “There had been no treatment for cancers that frequently express this mutation,” the FDA announced.
Bayer, the company behind the drug has promised to make it affordable to all who need it.
